RxDoctor Payments Data

Kimberly Cooney, PA

Medical · Irmo, SCNPI 1558616581

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 335 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 44 manufacturers, the largest accounting for just 12.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,864, more than ten times the $12 reported in 2021.

$5,460in general payments, 2019–2025

Across 335 payments — averaging $16.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$677
  • Otsuka America Pharmaceutical, Inc.$480
  • AbbVie$421
  • Novo Nordisk$411
  • Abbott$388
  • Lilly USA, LLC$342
  • plus $3K from 38 others

What the payments were for

  • Food & beverage$5,460100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,460 in reported general payments places this provider in the 85th percentile of 384 medical providers in South Carolina.

See all medical providers in South Carolina

Medicare billing

Part B allowed, 2024
$65,280
Medicare patients
402
Services billed
1,191

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$13,767
EliquisApixaban14$9,694
Albuterol Sulfate HfaAlbuterol Sulfate30$1,002
Duloxetine Hcl26$559
Levothyroxine Sodium40$526
Atorvastatin Calcium35$468
Gabapentin25$428
Losartan Potassium38$410
Valsartan12$315
Methylprednisolone57$303
Metoprolol Succinate31$291
Mirtazapine11$282
Tamsulosin Hcl22$266
Olmesartan Medoxomil19$260
Montelukast Sodium17$248

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$16$13,76721 claims
PfizerEliquis$68$9,69414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 384 medical providers in South Carolina.

Other medical in Irmo

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →